Department of Internal Diseases, Diabetology and Cardiometabolic Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland.
Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland.
Ann Transplant. 2022 Feb 15;27:e933420. doi: 10.12659/AOT.933420.
BACKGROUND Cardiac allograft vasculopathy (CAV) is the leading complication limiting the long-term survival of heart transplant (HTx) patients. The goal of this study was to assess carbohydrate metabolism disorders in relation to CAV intensification in heart transplant patients according to the ISHLT grading scheme. MATERIAL AND METHODS This retrospective study involved 477 HTx recipients undergoing angiographic observation for up to 20 years after transplantation. The patients were assigned to 4 groups on the basis of their carbohydrate metabolism status: without diabetes, with type 2 diabetes prior to HTx, with new-onset diabetes after transplantation, and with transient hyperglycemia. RESULTS In the study, 62.7% (n=299) of the patients manifested no diabetes after HTx, while 14.3% (n=68) of patients had type II diabetes prior to HTx and 18.4% (n=88) developed new-onset diabetes after transplantation. In total, 1442 coronary angiograms were taken in the specified control periods. CAV incidence increased over time after transplantation, reaching 11% after 1 year, 57% after 10 years, and 50% after 20 years. The longest survival time was observed for patients who had developed type II diabetes prior to HTx, but the difference was not statistically significant. The multivariate analysis failed to identify an independent risk factor for developing cardiac allograft vasculopathy. CONCLUSIONS Despite the relatively high rates of CAV and carbohydrate metabolism disorders in heart transplant patients, our retrospective analysis revealed no statistically significant link between these 2 diseases.
心脏同种异体移植血管病(CAV)是限制心脏移植(HTx)患者长期存活的主要并发症。本研究的目的是根据 ISHLT 分级方案评估心脏移植患者中与 CAV 加重相关的碳水化合物代谢紊乱。
本回顾性研究纳入了 477 例接受 HTx 并在移植后长达 20 年进行血管造影观察的患者。根据患者的碳水化合物代谢状态,将其分为 4 组:无糖尿病、HTx 前患有 2 型糖尿病、移植后新发糖尿病和短暂性高血糖。
在研究中,62.7%(n=299)的患者在 HTx 后没有出现糖尿病,而 14.3%(n=68)的患者在 HTx 前患有 2 型糖尿病,18.4%(n=88)的患者在移植后新发糖尿病。在指定的对照期内,共进行了 1442 次冠状动脉造影。CAV 的发生率在移植后随时间增加,1 年后达到 11%,10 年后达到 57%,20 年后达到 50%。最长的生存时间观察到在 HTx 前患有 2 型糖尿病的患者,但差异无统计学意义。多变量分析未能确定发生心脏同种异体移植血管病的独立危险因素。
尽管心脏移植患者的 CAV 和碳水化合物代谢紊乱发生率相对较高,但我们的回顾性分析未发现这两种疾病之间存在统计学显著关联。